

## Special Issue

# Future Challenges of Targeted Therapy of Cancers

### Message from the Guest Editor

The scope of this Special Issue is to collect papers referring to updates in the targeted therapy of cancers. As future individualized therapy is predicted to be mainly based on gene profile, the genetic background should be more deeply understood, from cell lines to circulating tumor cells and tissue biomarkers. Data concerning the heterogeneity of tumors and a deeply understanding of their environment could also have a therapeutic impact. Any research or review papers which may have implications in improving oncologic therapy are welcome, and we encourage the presentation of clinical trial results. If some papers are mainly based on in silico analyses or the examination of public gene databases, they should include an external validation of their own cohort.

### Guest Editor

Prof. Dr. Simona Gurzu

Department of Pathology, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology, 38 Gheorghe Marinescu Street, 540139 Targu Mures, Romania

### Deadline for manuscript submissions

closed (31 January 2024)



## Current Issues in Molecular Biology

an Open Access Journal  
by MDPI

Impact Factor 3.0  
CiteScore 3.7  
Indexed in PubMed



[mdpi.com/si/170562](https://mdpi.com/si/170562)

*Current Issues in Molecular Biology*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cimb@mdpi.com](mailto:cimb@mdpi.com)

[mdpi.com/journal/  
cimb](https://mdpi.com/journal/cimb)





# Current Issues in Molecular Biology

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 3.7  
Indexed in PubMed



[mdpi.com/journal/  
cimb](https://mdpi.com/journal/cimb)



## About the Journal

### Message from the Editor-in-Chief

---

#### Editor-in-Chief

Prof. Dr. Madhav Bhatia

Department of Pathology and Biomedical Science, University of Otago,  
Christchurch, 2 Riccarton Avenue, P.O. Box 4345, Christchurch 8140,  
New Zealand

---

#### Author Benefits

##### High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC,  
PubMed, Embase, CAPus / SciFinder, FSTA, AGRIS, and  
other databases.

##### Rapid Publication:

manuscripts are peer-reviewed and a first decision is  
provided to authors approximately 17.8 days after  
submission; acceptance to publication is undertaken in 2.7  
days (median values for papers published in this journal in  
the first half of 2025).

##### Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and  
reviewer names are published annually in the journal.